Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 3/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6432685 | 1.00 | CA2 (0.49) | CA2CA1PDK1PDK2PDK3 | |
| Trifluoroacetic Acid SCHEMBL6434379 | 0.90 | CA2 (0.46) | CA2CA1PDK1PDK2PDK3 | |
| Trifluoroacetic Acid SCHEMBL6434983 | 0.89 | CA2 (0.46) | CA2CA1PDK1PDK2PDK3 | |
| Trifluoroacetic Acid SCHEMBL6434979 | 0.89 | CA2 (0.46) | CA2CA1PDK1PDK2PDK3 | |
| Trifluoroacetic Acid SCHEMBL6435207 | 0.88 | GRN (0.51) | CA2CA1PDK1PDK2PDK3 | |
| Trifluoroacetic Acid SCHEMBL6435197 | 0.88 | GRN (0.51) | CA2CA1PDK1PDK2PDK3 | |
| SCHEMBL6437336 | 0.85 | ROCK2 (0.48) | CA2CA1HPGDS | |
| Trifluoroacetic Acid SCHEMBL6434862 | 0.85 | CTSA (0.42) | — | |
| SCHEMBL6434387 | 0.84 | MRGPRX4 (0.37) | CA2CA1PDK1PDK2PDK3 | |
| SCHEMBL6434672 | 0.84 | CTSL (0.46) | CA2CA1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CA2 3285/4885CA1 3943/4885PDK1 3923/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CA2 3285/4885CA1 3943/4885PDK1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.